BRAF and melanoma: Next, we examined these responses in SKMEL5 and G361 cells, because these BRAF mutant melanoma cells are intrinsically resistant to BRAF inhibitors and are ∼10 fold less sensitive to PLX4720 than A375 and Colo829 (Supplemental Figure 2E).